Ambrisentan
  
Side effects 
	
		
Options: 
			
			Hide MedDRA Preferred Terms
			
		
	
	
| MedDRA Preferred Term | Side effect | Data for drug | Placebo | Labels | 
|  | 1 | 2 | 3 | 4 | 5 | 6 | 
| Oedema peripheral | Oedema peripheral | 17.2% - 28.4% | 10.6% | x | x | x | x | x | x | 
| Headache | Headache | very common, 14.6% - 19.4% | 13.6% | x |  | x | x | x | x | 
| Sinus headache | Sinus headache | very common |  |  |  | x | x | x |  | 
| Migraine | Migraine | very common |  |  |  | x | x | x |  | 
| Dizziness | Dizziness | postmarketing, 6.92% - 8.96% | 9.85% |  | x | x | x | x | x | 
| Syncope |  |  |  |  | x |  |  |  | 
| Cough | Cough | 5.38% - 7.46% | 6.06% |  |  |  | x | x | x | 
| Upper respiratory tract infection | Upper respiratory tract infection | 4.62% - 7.46% | 6.06% |  |  |  | x | x | x | 
| Nasal congestion | Nasal congestion | common, 5.38% - 10.4% | 1.52% | x | x | x | x | x | x | 
| Dyspnoea | Dyspnoea exacerbated | 1.49% - 7.69% | 6.06% |  |  |  | x | x | x | 
| Dyspnoea | postmarketing, 4.21% - 5.38% | 3.03% | x |  | x | x | x | x | 
| Asthenia | Fatigue | postmarketing, 4.48% - 5.38% | 4.55% |  | x | x | x | x |  | 
| Asthenia | postmarketing |  |  | x | x | x | x |  | 
| Fatigue | Fatigue | postmarketing, 4.48% - 5.38% | 4.55% |  | x | x | x | x |  | 
| Palpitations | Palpitations | common, 3.85% - 4.6% | 2.27% | x |  | x | x | x | x | 
| Nausea | Nausea | postmarketing, 3.85% - 4.48% | 9.09% |  | x | x | x | x | x | 
| Constipation | Constipation | common, 3.08% - 5.97% | 1.52% | x |  | x | x | x | x | 
| Flushing | Flushing | common, 1.49% - 3.85% | 0.758% | x | x | x | x | x | x | 
| Epistaxis | Epistaxis | 1.54% - 5.97% | 3.79% |  |  | x | x | x |  | 
| Nasopharyngitis | Nasopharyngitis | common, 2.99% - 5.38% | 0.758% | x |  | x | x | x | x | 
| Sinusitis | Sinusitis | common, 3.07% - 4.48% | 0% | x | x | x | x | x | x | 
| Abdominal pain | Abdominal pain | common, 2.99% - 3.08% | 0.758% | x |  | x | x | x | x | 
| Gastrointestinal pain | Abdominal pain | common, 2.99% - 3.08% | 0.758% | x |  | x | x | x | x | 
| Bronchitis | Bronchitis | 1.49% - 4.62% | 3.79% |  |  |  | x | x |  | 
| Chest pain | Chest pain | 1.49% - 4.62% | 2.27% |  |  | x | x | x | x | 
| Chest discomfort |  |  |  |  |  |  |  | x | 
| Right ventricular failure | Right ventricular failure | 1.49% - 4.62% | 12.1% |  |  |  | x | x | x | 
| Aspartate aminotransferase increased | Aspartate aminotransferase increased | 1.54% - 2.99% | 3.79% |  |  |  | x | x |  | 
| Insomnia | Insomnia | 1.49% - 2.31% | 3.03% |  |  |  | x | x | x | 
| Arthralgia | Arthralgia | 0.769% - 2.99% | 3.79% |  |  |  | x | x | x | 
| Musculoskeletal discomfort | Arthralgia | 0.769% - 2.99% | 3.79% |  |  |  | x | x | x | 
| Myalgia |  |  |  |  |  |  |  | x | 
| Urinary tract infection | Urinary tract infection | 1.49% - 1.54% | 6.06% |  |  |  | x | x |  | 
| Pulmonary hypertension | Pulmonary hypertension | 0.769% - 1.49% | 5.3% | x |  |  | x | x | x | 
| Dermatitis | Rash | postmarketing, uncommon |  |  | x | x | x | x | x | 
| Rash | Rash | postmarketing, uncommon |  |  | x | x | x | x | x | 
| Hypersensitivity | Hypersensitivity | postmarketing, uncommon |  |  | x | x | x | x | x | 
| Anaemia | Anaemia | postmarketing |  |  | x | x | x | x | x | 
| Angioedema | Angioedema | postmarketing |  |  | x | x |  |  | x | 
| Gastrointestinal disorder | Gastrointestinal disorder | postmarketing |  |  |  | x | x | x | x | 
| Cardiac disorder | Cardiac disorder | postmarketing |  |  |  | x | x | x | x | 
| Cardiac failure | Cardiac failure | postmarketing |  |  | x | x | x | x |  | 
| Hepatitis | Hepatitis | postmarketing |  |  | x |  |  |  |  | 
| Mediastinal disorder | Mediastinal disorder | postmarketing |  |  |  | x | x | x | x | 
| Nervous system disorder | Nervous system disorder | postmarketing |  |  |  | x | x | x |  | 
| Vomiting | Vomiting | postmarketing |  |  | x | x | x | x |  | 
| Hepatic failure | Hepatic failure | postmarketing |  |  | x |  |  |  |  | 
| Liver injury | Liver injury | postmarketing |  |  | x | x | x | x |  | 
| Traumatic liver injury | Liver injury | postmarketing |  |  | x | x | x | x |  | 
| Hepatotoxicity | Hepatotoxicity | postmarketing |  |  | x |  |  |  |  | 
| Autoimmune hepatitis | Autoimmune hepatitis | postmarketing |  |  |  | x | x | x |  | 
| Hepatobiliary disease | Hepatobiliary disease | postmarketing |  |  |  | x | x | x |  | 
| Hepatic congestion | Hepatic congestion | postmarketing |  |  | x |  |  |  |  | 
| Fluid retention | Fluid retention | postmarketing |  | x | x | x | x | x | x | 
| Transaminases increased | Transaminases increased | postmarketing |  |  |  | x | x | x |  | 
| Angina pectoris | Angina pectoris |  |  |  |  |  |  |  | x | 
| Decreased appetite | Anorexia |  |  |  |  |  |  |  | x | 
| Mental disorder | Mental disorder |  |  |  |  |  |  |  | x | 
| Breast disorder | Breast disorder |  |  |  |  |  |  |  | x | 
| Infection | Infection |  |  |  |  |  |  |  | x | 
| Contusion | Contusion |  |  |  |  |  |  |  | x | 
| Diarrhoea | Diarrhoea |  |  |  |  | x |  |  | x | 
| Oedema | Oedema |  |  |  |  |  |  |  | x | 
| Body temperature increased | Body temperature increased |  |  |  |  |  |  |  | x | 
| Gastritis | Gastritis |  |  |  |  |  |  |  | x | 
| Blood disorder | Blood disorder |  |  |  |  |  |  |  | x | 
| Haemorrhage | Haemorrhage |  |  |  |  |  |  |  | x | 
| Haemoglobin | Haemorrhage |  |  |  |  |  |  |  | x | 
| Hypokalaemia | Hypokalaemia |  |  |  |  |  |  |  | x | 
| Hypotension | Hypotension |  |  |  |  | x |  |  |  | 
| Immune system disorder | Immune system disorder |  |  |  |  | x | x | x | x | 
| Influenza | Influenza |  |  |  |  |  |  |  | x | 
| Muscle spasms | Cramp muscle |  |  |  |  |  |  |  | x | 
| Nocturia | Nocturia |  |  |  |  |  |  |  | x | 
| Pharyngitis | Pharyngitis |  |  |  |  |  |  |  | x | 
| Pleural effusion | Pleural effusion |  |  |  |  |  |  |  | x | 
| Pneumonia | Pneumonia |  |  |  |  |  |  |  | x | 
| Pruritus | Pruritus |  |  |  |  | x |  |  | x | 
| Pulmonary oedema | Pulmonary oedema |  |  |  | x |  |  |  |  | 
| Pulmonary veno-occlusive disease | Pulmonary veno-occlusive disease |  |  |  | x |  |  |  |  | 
| Rales | Rales |  |  |  |  |  |  |  | x | 
| Rhinitis | Rhinitis |  |  |  |  | x |  |  | x | 
| Skin ulcer | Skin ulcer |  |  |  |  |  |  |  | x | 
| Shock | Syncope |  |  |  |  | x |  |  |  | 
| Syncope | Syncope |  |  |  |  | x |  |  |  | 
| Loss of consciousness | Syncope |  |  |  |  | x |  |  |  | 
| Tachycardia | Tachycardia |  |  |  |  |  |  |  | x | 
| Urethral disorder | Urinary tract disorder |  |  |  |  |  |  |  | x | 
| Urinary tract disorder | Urinary tract disorder |  |  |  |  |  |  |  | x | 
| Angiopathy | Angiopathy |  |  |  |  | x | x | x |  | 
| Wheezing | Wheezing |  |  |  |  |  |  |  | x | 
| Haemoglobin decreased | Haemoglobin decreased |  |  |  |  | x | x | x | x | 
| Malnutrition | Malnutrition |  |  |  |  |  |  |  | x | 
| Myalgia | Myalgia |  |  |  |  |  |  |  | x | 
| Abdominal pain upper | Abdominal pain upper |  |  |  |  |  |  |  | x | 
| Discomfort | Discomfort |  |  |  |  | x |  |  |  | 
| Chest discomfort | Chest discomfort |  |  |  |  |  |  |  | x | 
| Non-cardiac chest pain | Non-cardiac chest pain |  |  |  |  |  |  |  | x | 
| Haematocrit decreased | Haematocrit decreased |  |  |  |  | x |  |  | x | 
| Infestation | Infestation NOS |  |  |  |  |  |  |  | x | 
| Sleep disorder | Sleep disorder |  |  |  |  |  |  |  | x | 
| Sperm concentration decreased | Sperm count decreased |  |  |  | x |  |  |  |  | 
| Vaginal haemorrhage | Vaginal haemorrhage |  |  |  |  |  |  |  | x | 
	 
 
  Indications
	Information about indications was extracted from the indications and usage sections of the labels.
	
 
	  
	  
		| Side effects: | 12 | 
|---|
		| Source: | FDA | 
|---|
		 
	  
	  
		| Side effects: | 23 | 
|---|
		| Source: | FDA Structured Product Label | 
|---|
		 
	  
	  
		| Side effects: | 44 | 
|---|
		| Source: | EMA | 
|---|
		 
	  
	  
		| Side effects: | 46 | 
|---|
		| Source: | medicines.org.au | 
|---|
		 
	  
	  
		| Side effects: | 46 | 
|---|
		| Source: | Medsafe | 
|---|
		 
	  
	  
		| Side effects: | 65 | 
|---|
		| Source: | Health Canada | 
|---|
		 
	  
  
 
  
	Color scheme:
	  
	  standard – alternative
	  
	
	
|  |  | 100% | 
|  |  | 75% | 
|  |  | 50% | 
|  |  | 10% | 
|  |  | frequent (1% to 100%) | 
|  |  | infrequent (0.1% to 1%) | 
|  |  | rare (<0.1%) | 
|  |  | postmarketing | 
|  |  | 0% | 
|  |  | no frequency information | 
|  |  | not found on label |